Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 14, 2020; 94 (15 Supplement) Wednesday, April 29

A Phase 1 Study of PBT434, a Novel Small Molecule Inhibitor of α-Synuclein Aggregation, in Adult and Older Adult Volunteers (4871)

David Stamler, Margaret Bradbury, Cynthia Wong, Elliot Offman
First published April 14, 2020,
David Stamler
1Alterity Therapeutics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret Bradbury
1Alterity Therapeutics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Wong
1Alterity Therapeutics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elliot Offman
2Certara Strategic Consulting
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
A Phase 1 Study of PBT434, a Novel Small Molecule Inhibitor of α-Synuclein Aggregation, in Adult and Older Adult Volunteers (4871)
David Stamler, Margaret Bradbury, Cynthia Wong, Elliot Offman
Neurology Apr 2020, 94 (15 Supplement) 4871;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Evaluate the safety, tolerability and pharmacokinetics of PBT434 in healthy adult and older adult volunteers.

Background: PBT434 is a novel, brain penetrant small molecule inhibitor of α-synuclein aggregation. In transgenic mouse models of Parkinson disease (PD;A53T) and Multiple System Atrophy (MSA;PLP-α-Syn), PBT434 reduced α-synuclein aggregation and markers of oxidative stress, preserved neurons, improved motor function and reduced glial cell inclusions (PLP-α-Syn). PBT434 is thought to act by redistributing labile iron across membranes in the CNS. The affinity of PBT434 for iron is lower than for iron trafficking proteins, e.g., transferrin.

Design/Methods: In this randomized, double-blind, placebo-controlled study, adult subjects received oral single doses (8/cohort) 50–600 mg or 8 days dosing (10/cohort) at 100, 200 or 250 mg bid. Older adults (≥65 years) received 250 mg bid. Serial blood samples were collected post-dose and CSF was sampled at 1.5 or 11 hours post-dose at 200–250 mg bid at steady state. Safety was assessed with physical examination, adverse events (AEs), laboratory tests and 12-lead ECGs.

Results: PBT434 was rapidly absorbed with a Tmax of 0.5–2 hours and demonstrated dose-dependent pharmacokinetics after single and multiple doses. Mean elimination half-life up to 9.3 hours was observed independent of dose. CSF concentrations near Tmax were 102.5 to 229.5 ng/mL. AE rates were similar for PBT434 and placebo. All AEs were mild to moderate in severity. There were no serious AEs or AEs leading to discontinuation. The AE profile was similar for adult and ≥65 year-old volunteers. There were no clinically significant vital sign, laboratory or 12-lead ECG findings.

Conclusions: PBT434 is an orally bioavailable, brain penetrant, small molecule inhibitor of α-synuclein aggregation. CSF concentrations at doses ≥200 mg bid were greater than those associated with efficacy in animal models of PD and MSA. PBT434 was safe and well tolerated at all doses. PBT434 has potential to treat synucleinopathies.

Disclosure: Dr. Stamler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Former employee of Teva Pharmaceuticals; salary and benefits from Auspex Pharmaceuticals. Patents pending: US20160346270, US20160287574.. Dr. Bradbury has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alterity Therapeutics. Dr. Wong has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alterity. Dr. Offman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alterity Therapeutics.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise